|
Mutation Information
|
Mutation Site
|
S202G |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.S202G+rt.M204V+rt.L180M |
|
Relevant Drug
|
lamivudine (LAM);entecavir (ETV) |
Literature Information
|
PubMed PMID
|
23237841
|
|
Published Year
|
2013 |
|
Journal
|
Bioorganic & medicinal chemistry letters |
|
Title
|
2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. |
|
Author
|
Rawal RK,Singh US,Chavre SN,Wang J,Sugiyama M,Hung W,Govindarajan R,Korba B,Tanaka Y,Chu CK |
|
Evidence
|
Novel 2'-fluoro-6'-methylene-carbocyclic adenosine (FMCA) monophosphate prodrug (FMCAP) was synthesized and evaluated for its in vitro anti-HBV potency against a lamivudine-entecavir resistant clone (L180M+M204V+S202G).
|
|
|
HBV Mutation Detail Information